News

The IHT Landscape: Why Planning Has Never Mattered More

Calculus has made a follow-on investment in Optalitix, an award-winning technology company delivering low-code SaaS platforms, advanced data analytics, and AI-driven modelling solutions to insurers and financial institutions.

This is OBT’s third major pharma collaboration within the past 12 months and reflects strong validation of the OGAP®-Verify platform’s potential to drive oncology innovation.

The data shows complete tumour eradication and durable protection in a state-of-the-art aggressive brain cancer model that closely mimics human glioblastoma (GBM).

Resurrect Bio has announced a joint development agreement to tackle some of the most economically devastating diseases currently affecting corn production in the United States.

Wonderhood Studios, a Calculus portfolio company, has launched its first major campaign since securing the Waitrose account.

Resurrect is biotechnology company revolutionizing agriculture by equipping crops with genetic defenses against disease.

Advisers and investors are increasingly looking beyond traditional structures to ensure client portfolios are genuinely diversified, not just by provider, but by sector, asset behaviour, and risk drivers.

Two portfolio companies make The Sunday Times 100 Tech ranking.

Smartr365 launches full mortgage submissions with Halifax

Oxford BioTherapeutics has agreed a new research collaboration with GSK to identify novel cancer targets using its OGAP-Verify platform.

Waitrose’s 2025 Christmas advertising campaign is a four-minute festive romantic comedy short film called “The Perfect Gift,” starring Keira Knightley alongside comedian Joe Wilkinson

This is Calculus’ understanding of the budget. Tax treatment is subject to change and depends on individual circumstances.

The exit has delivered up to a 1.8x return for Calculus investors. For the Calculus VCT, it generates an additional £1.53 million in cash for the portfolio.

Harrogate and London-based Grateful – the automated tip pooling and tronc platform – has raised £1.5 million ($2m) seed funding from Calculus Capital.

Calculus invests as part of a £70million Series A financing to drive clinical development of therapies for hard to treat cancers.

Arecor partners with Sequel Med Tech on AT278 insulin and raises up to $11m from Ligand, accelerating Phase 2 readiness, extending cash runway to 2027, and positioning for next-generation diabetes care and significant shareholder value creation.

Calculus portfolio company C4X Discovery selects a best-in-class oral IBD candidate, highlighting innovation and value creation in UK biotech.

Here we speak to Richard Moore, Co-Head of Investments, on the key lessons learned and how that informs our investment strategy in the technology space.

Calculus portfolio company Optalitix, a leading insurtech innovator, has announced the expansion of its flagship pricing platform, Optalitix Quote, into the reinsurance market.

Stuffed is due to commence filming in September

Calculus has invested in EnsiliTech, a company revolutionising the transport of life-saving medicines.

The Annual General Meeting (AGM) of Calculus VCT plc (the “Company”) will be held virtually at 3pm on 23rd of September 2025.

At Calculus Capital, managers of the Calculus VCT, the Calculus EIS Fund, and the Calculus Knowledge Intensive EIS Fund, we are proud to back WorkL, the employee engagement platform founded by Lord Mark Price, former Waitrose boss and UK trade minister.